{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:12:47Z","timestamp":1790626367355,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1111\/bjd.15827","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T06:36:35Z","timestamp":1504506995000},"page":"999-1003","source":"Crossref","is-referenced-by-count":19,"title":["A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal"],"prefix":"10.1093","volume":"177","author":[{"given":"S.","family":"Weidinger","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergy; University Hospital Schleswig-Holstein; Campus Kiel, Schittenhelmstrasse 7 24105 Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Baurecht","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergy; University Hospital Schleswig-Holstein; Campus Kiel, Schittenhelmstrasse 7 24105 Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Center for Evidence-based Healthcare; Medizinische Fakult\u00e4t Carl Gustav Carus; TU Dresden; Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,4]]},"reference":[{"key":"10.1111\/bjd.15827-BIB0001|bjd15827-cit-0001","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jaci.2007.11.004","article-title":"Is eczema really on the increase worldwide?","volume":"121","author":"Williams","year":"2008","journal-title":"J Allergy Clin Imunol"},{"key":"10.1111\/bjd.15827-BIB0002|bjd15827-cit-0002","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaci.2004.01.778","article-title":"The natural course of atopic dermatitis from birth to age 7 years and the association with asthma","volume":"113","author":"Illi","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.15827-BIB0003|bjd15827-cit-0003","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/all.12112","article-title":"Characterization of different courses of atopic dermatitis in adolescent and adult patients","volume":"68","author":"Garmhausen","year":"2013","journal-title":"Allergy"},{"key":"10.1111\/bjd.15827-BIB0004|bjd15827-cit-0004","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjd.12196","article-title":"Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort","volume":"168","author":"Ballardini","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0005|bjd15827-cit-0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4370","article-title":"Systematic review of treatments for atopic eczema","volume":"4","author":"Hoare","year":"2000","journal-title":"Health Technol Assess"},{"issue":"Suppl. 3","key":"10.1111\/bjd.15827-BIB0006|bjd15827-cit-0006","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1468-3083.2012.04522.x","article-title":"Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities","volume":"26","author":"Castela","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15827-BIB0007|bjd15827-cit-0007","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2011.10449.x","article-title":"Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency","volume":"165","author":"Aubert-Wastiaux","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0008|bjd15827-cit-0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1525-1470.2012.01808.x","article-title":"Factors associated with steroid phobia in caregivers of children with atopic dermatitis","volume":"30","author":"Kojima","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1111\/bjd.15827-BIB0009|bjd15827-cit-0009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.2000.03473.x","article-title":"Topical corticosteroid phobia in patients with atopic eczema","volume":"142","author":"Charman","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0010|bjd15827-cit-0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40264-015-0287-7","article-title":"Topical corticosteroid-induced skin atrophy: a comprehensive review","volume":"38","author":"Barnes","year":"2015","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.15827-BIB0011|bjd15827-cit-0011","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2133.2005.06592.x","article-title":"A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis","volume":"152","author":"Reitamo","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0012|bjd15827-cit-0012","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1600-0625.2011.01335.x","article-title":"Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography","volume":"20","author":"Aschoff","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1111\/bjd.15827-BIB0013|bjd15827-cit-0013","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaci.2009.03.032","article-title":"Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis","volume":"123","author":"Jensen","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.15827-BIB0014|bjd15827-cit-0014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1525-1470.2011.01445.x","article-title":"Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients","volume":"28","author":"Hong","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1111\/bjd.15827-BIB0015|bjd15827-cit-0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0016|bjd15827-cit-0016","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15827-BIB0017|bjd15827-cit-0017","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"330","author":"Ashcroft","year":"2005","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0018|bjd15827-cit-0018","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/09546630903401470","article-title":"Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials","volume":"21","author":"Chen","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.15827-BIB0019|bjd15827-cit-0019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2133.2011.10363.x","article-title":"Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors","volume":"165","author":"Tennis","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0020|bjd15827-cit-0020","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0021|bjd15827-cit-0021","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0140-6736(02)07816-9","article-title":"Blinding in randomised trials: hiding who got what","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/bjd.15827-BIB0022|bjd15827-cit-0022","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0023|bjd15827-cit-0023","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0024|bjd15827-cit-0024","unstructured":"CONSORT Transparent reporting of trials http:\/\/www.consort-statement.org\/downloads\/consort-statement"},{"key":"10.1111\/bjd.15827-BIB0025|bjd15827-cit-0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1399-3038.2009.00914.x","article-title":"Development of atopic dermatitis in the DARC birth cohort","volume":"21","author":"Eller","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1111\/bjd.15827-BIB0026|bjd15827-cit-0026","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0027|bjd15827-cit-0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-8-24","article-title":"Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network","volume":"8","author":"Simera","year":"2010","journal-title":"BMC Med"},{"key":"10.1111\/bjd.15827-BIB0028|bjd15827-cit-0028","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1111\/bjd.15827-BIB0029|bjd15827-cit-0029","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/bjd.15827-BIB0030|bjd15827-cit-0030","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0031|bjd15827-cit-0031","doi-asserted-by":"crossref","first-page":"c723","DOI":"10.1136\/bmj.c723","article-title":"The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed","volume":"340","author":"Hopewell","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/bjd.15827-BIB0032|bjd15827-cit-0032","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.2010.651","article-title":"Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes","volume":"303","author":"Boutron","year":"2010","journal-title":"JAMA"},{"key":"10.1111\/bjd.15827-BIB0033|bjd15827-cit-0033","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"Dwan","year":"2008","journal-title":"PLOS ONE"},{"key":"10.1111\/bjd.15827-BIB0034|bjd15827-cit-0034","first-page":"674","article-title":"Establishing equivalence or non-inferiority in clinical trials: part 20 of a series on evaluation of scientific publications","volume":"109","author":"Wellek","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1111\/bjd.15827-BIB0035|bjd15827-cit-0035","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"10.1111\/bjd.15827-BIB0036|bjd15827-cit-0036","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/sim.2584","article-title":"Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin","volume":"25","author":"Committee for Medicinal Products for Human Use; Efficacy Working Party; Committee for Release for Consultation","year":"2006","journal-title":"Stat Med"},{"key":"10.1111\/bjd.15827-BIB0037|bjd15827-cit-0037","unstructured":"Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Non-inferiority clinical trials to establish effectiveness. Guidance for industry https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM202140.pdf"},{"key":"10.1111\/bjd.15827-BIB0038|bjd15827-cit-0038","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1365-2133.2006.07184.x","article-title":"A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema","volume":"154","author":"Pitt","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15827-BIB0039|bjd15827-cit-0039","first-page":"511","article-title":"\u2018Spin\u2019 in scientific writing: scientific mischief and legal jeopardy","volume":"26","author":"Fletcher","year":"2007","journal-title":"Med Law"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15827","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15827\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:28:49Z","timestamp":1676384929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/177\/4\/999\/6674083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15827","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,4]]}}}